person · Reporting owner
Duprey Lauren Rusckowski
Disclosed activity across 1 company
Sign in to followReported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| TAKEDA PHARMACEUTICAL CO LTDTAK · Entity 2662 | Chief Transformation Officer | September 14, 2026 | September 16, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
TAKEDA PHARMACEUTICAL CO LTD
Report date September 14, 2026 · Filed September 16, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| American Depositary SharesSEC Table I · non-derivative | Direct | 191,522 |
Reported balance
After 2026-09-14 transaction · row 1
1 source rowRow 1 · 2026-09-14 · Sale · Disposed 34,535 · Balance 191,522 |
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 14, 2026 Filed Sep 16, 2026 01:12 UTC | TAKEDA PHARMACEUTICAL CO LTD TAK · Entity 2662 | SaleAmerican Depositary Shares | 34,535 | $18.54 | $640,278.90 |
DisclosureSEC source: 0001395064-26-000340 · wk-form4_1789521164.xml · nonDerivative · entry 1 Duprey Lauren Rusckowski · CIK 0001977746 · Chief Transformation Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 191,522 Read SEC document |
| August 10, 2026 Filed Aug 13, 2026 01:51 UTC | TAKEDA PHARMACEUTICAL CO LTD TAK · Entity 2662 | SaleAmerican Depositary Shares | 47,586 | $17.10 | $813,720.60 |
DisclosureSEC source: 0001493152-26-037509 · ownership.xml · nonDerivative · entry 1 Duprey Lauren Rusckowski · CIK 0001977746 · Chief Transformation Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 226,057 F1 · kind: Represents a mandatory sale to cover taxes associated with the vesting of equity awards held by the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average price. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| July 01, 2026 Filed Jul 6, 2026 22:03 UTC | TAKEDA PHARMACEUTICAL CO LTD TAK · Entity 2662 | GrantAmerican Depositary Shares | 45,140 | $0.00 | $0.00 |
DisclosureSEC source: 0001395064-26-000248 · wk-form4_1783375382.xml · nonDerivative · entry 1 Duprey Lauren Rusckowski · CIK 0001977746 · Chief Transformation Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 273,643 F1 · shares: Represents an award of restricted stock units (RSUs). Each RSU represents a contingent right to receive one American Depositary Share. The RSUs vest in three equal annual installments beginning on July 1, 2027. Read SEC document |
| April 27, 2026 Filed Apr 28, 2026 10:05 UTC | TAKEDA PHARMACEUTICAL CO LTD TAK · Entity 2662 | GrantAmerican Depositary Shares | 59,990 | $0.00 | $0.00 |
DisclosureSEC source: 0001395064-26-000130 · wk-form4_1777370731.xml · nonDerivative · entry 1 Duprey Lauren Rusckowski · CIK 0001977746 · Chief Transformation Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 228,503 F1 · kind: On July 1, 2023, the reporting person was granted an award of restricted stock units (RSUs), which vest in the form of American Depositary Shares based upon the achievement of the specified performance metrics, including core revenue, core operating profit, and important R&D milestones. On April 27, 2026, the Compensation Committee of the Board of Directors determined the number of RSUs to be awarded based on these performance metrics, which amount is reported above. F2 · balance_after: Includes 146,762 restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one American Depositary Share. The RSUs vest on the following schedule: July 1, 2026 (100,658 shares), July 1, 2027 (30,488 shares) and July 1, 2028 (15,616 shares). Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.